{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T22:02:20Z","timestamp":1787868140358,"version":"build-2784847793"},"reference-count":192,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ibroneuroscience.org","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuroscience"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.neuroscience.2024.11.078","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T17:05:53Z","timestamp":1733763953000},"page":"499-518","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["\u201cCurrent and emerging drug therapies in Alzheimer\u2019s disease: A pathophysiological Perspective\u201d"],"prefix":"10.1016","volume":"565","author":[{"given":"Aparajita","family":"Aparajita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Unnati","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.neuroscience.2024.11.078_b0005","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.3324\/haematol.2011.043018","article-title":"A pilot trial of deferiprone for neurodegeneration with brain iron accumulation","volume":"96","author":"Abbruzzese","year":"2011","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.neuroscience.2024.11.078_b0010","article-title":"Alzheimer's Disease Neuroimaging Initiative. APOE \u03b54\/\u03b54 homozygotes with early Alzheimer's disease show accelerated hippocampal atrophy and cortical thinning that correlates with cognitive decline","volume":"6","author":"Abushakra","year":"2020","journal-title":"Alzheimer's & Dementia: Translational Research & Clinical Interventions"},{"issue":"3","key":"10.1016\/j.neuroscience.2024.11.078_b0015","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.neuroscience.2024.11.078_b0020","unstructured":"Alzforum [Internet]. JNJ-63733657. [cited 2024 Feb 19]. Available from: https:\/\/www.alzforum.org\/therapeutics\/jnj-63733657."},{"key":"10.1016\/j.neuroscience.2024.11.078_b0025","unstructured":"Alzforum. ABBV-916. [Internet]. Available from: https:\/\/www.alzforum.org\/therapeutics\/abbv-916#:\u223c:text=ABBV%2D916%20is%20a%20monoclonal,to%20Lilly's%20donanemab%20and%20remternetug."},{"key":"10.1016\/j.neuroscience.2024.11.078_b0030","unstructured":"Alzheimer\u2019s Disease Cooperative Study. REMEMBER Phase 3 Clinical Trial of Remternetug in People with Early Alzheimer\u2019s Disease. [Internet]. Available from: https:\/\/www.alzforum.org\/therapeutics\/remternetug."},{"key":"10.1016\/j.neuroscience.2024.11.078_b0035","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.neuropharm.2017.01.010","article-title":"Modulation of neuroinflammation and pathology in the 5XFAD mouse model of Alzheimer's disease using a biased and selective beta-1 adrenergic receptor partial agonist","volume":"116","author":"Ardestani","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuroscience.2024.11.078_b0040","first-page":"140","article-title":"Lenalidomide induced reversible parkinsonism, dystonia, and dementia in subclinical Creutzfeldt-Jakob disease","volume":"393","author":"Argente-Escrig","year":"2018","journal-title":"J. NeurolSci."},{"issue":"1","key":"10.1016\/j.neuroscience.2024.11.078_b0050","doi-asserted-by":"crossref","first-page":"6760","DOI":"10.1038\/ncomms7760","article-title":"Ferritin levels in the cerebrospinal fluid predict Alzheimer\u2019s disease outcomes and are regulated by APOE","volume":"6","author":"Ayton","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neuroscience.2024.11.078_b0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1742-2094-8-79","article-title":"Microglial p38\u03b1 MAPK is a key regulator of proinflammatory cytokine up-regulation induced by toll-like receptor (TLR) ligands or beta-amyloid (A\u03b2)","volume":"8","author":"Bachstetter","year":"2011","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.neuroscience.2024.11.078_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2022.101619","article-title":"Oxidative stress: The core pathogenesis and mechanism of Alzheimer\u2019s disease","volume":"77","author":"Bai","year":"2022","journal-title":"Ageing Res. Rev."},{"issue":"3","key":"10.1016\/j.neuroscience.2024.11.078_b0065","first-page":"327","article-title":"Vascular dementia: pharmacological treatment approaches and perspectives","volume":"2","author":"Baskys","year":"2007","journal-title":"ClinInterv Aging"},{"issue":"5","key":"10.1016\/j.neuroscience.2024.11.078_b0070","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/s41591-021-01321-w","article-title":"Inhibition of phosphodiesterase-4D in adults with fragile X syndrome: a randomized, placebo-controlled, phase 2 clinical trial","volume":"27","author":"Berry-Kravis","year":"2021","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.neuroscience.2024.11.078_b0075","doi-asserted-by":"crossref","first-page":"549","DOI":"10.3233\/JAD-141626","article-title":"A clinical study of lupron depot in the treatment of women with Alzheimer's disease: preservation of cognitive function in patients taking an acetylcholinesterase inhibitor and treated with high dose lupron over 48 weeks","volume":"44","author":"Bowen","year":"2015","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.neuroscience.2024.11.078_b0080","first-page":"251","article-title":"Galectin-3, a novel endogenous TREM2 ligand, detrimentally regulates inflammatory response in Alzheimer\u2019s disease","volume":"138","author":"Boza-Serrano","year":"2019","journal-title":"ActaNeuropathol"},{"issue":"10","key":"10.1016\/j.neuroscience.2024.11.078_b0085","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1038\/s41587-022-01334-x","article-title":"Expanding RNAi therapeutics to extrahepatic tissues with lipophilic conjugates","volume":"40","author":"Brown","year":"2022","journal-title":"Nat. Biotechnol."},{"issue":"4","key":"10.1016\/j.neuroscience.2024.11.078_b0090","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0166-2236(03)00067-5","article-title":"The metallobiology of Alzheimer's disease","volume":"26","author":"Bush","year":"2003","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuroscience.2024.11.078_b0095","first-page":"1","article-title":"Introductory editorial to the special issue: Alzheimer\u2019s disease biomarkers and cognitive functioning along the Alzheimer\u2019s continuum","volume":"27","author":"Butts","year":"2023","journal-title":"Aging Neuropsychol. Cogn."},{"issue":"3","key":"10.1016\/j.neuroscience.2024.11.078_b0100","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0229850","article-title":"Brain shuttle neprilysin reduces central amyloid-\u03b2 levels","volume":"15","author":"Campos","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.neuroscience.2024.11.078_b0105","doi-asserted-by":"crossref","unstructured":"Canet G, Chevallier N, Perrier V, Desrumaux C, Givalois L (2019) Targeting glucocorticoid receptors: A new avenue for Alzheimer\u2019s disease therapy. Pathology, prevention and therapeutics of neurodegenerative disease 173-83.","DOI":"10.1007\/978-981-13-0944-1_15"},{"issue":"02","key":"10.1016\/j.neuroscience.2024.11.078_b0110","first-page":"01","article-title":"A REVIEW ON APPLICATIONS OF DEXMEDETOMIDINE (BXCL501) IN CNS DISORDERS","volume":"13","author":"Chabukswar","year":"2022","journal-title":"J AdvSci Res"},{"key":"10.1016\/j.neuroscience.2024.11.078_b0115","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.neulet.2016.11.022","article-title":"Activation of \u03b22-adrenergic receptor promotes dendrite ramification and spine generation in APP\/PS1 mice","volume":"636","author":"Chai","year":"2017","journal-title":"Neurosci Lett"},{"issue":"3","key":"10.1016\/j.neuroscience.2024.11.078_b0120","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.3233\/JAD-190864","article-title":"An exploratory phase IIa study of the PPAR delta\/gamma agonist T3D-959 assessing metabolic and cognitive function in subjects with mild to moderate Alzheimer\u2019s disease","volume":"73","author":"Chamberlain","year":"2020","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.neuroscience.2024.11.078_b0125","article-title":"Tumor necrosis factor \u03b1 inhibition for Alzheimer\u2019s disease","volume":"9","author":"Chang","year":"2017","journal-title":"J Cent NervSyst Dis"},{"issue":"4","key":"10.1016\/j.neuroscience.2024.11.078_b0130","doi-asserted-by":"crossref","first-page":"742","DOI":"10.4103\/1673-5374.230303","article-title":"Use of curcumin in diagnosis, prevention, and treatment of Alzheimer's disease","volume":"13","author":"Chen","year":"2018","journal-title":"Neural Regen Res"},{"issue":"5","key":"10.1016\/j.neuroscience.2024.11.078_b0135","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.neuron.2008.04.014","article-title":"Insulin receptor signaling regulates synapse number, dendritic plasticity, and circuit function in vivo","volume":"58","author":"Chiu","year":"2008","journal-title":"Neuron"},{"key":"10.1016\/j.neuroscience.2024.11.078_b0140","unstructured":"ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 -. Identifier NCT05543681, Safety and Efficacy of NBH12 in Subjects With Alzheimer's Disease. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05543681."},{"key":"10.1016\/j.neuroscience.2024.11.078_b0145","doi-asserted-by":"crossref","unstructured":"Corr\u00eaa SA, Eales KL (2012) The role of p38 MAPK and its substrates in neuronal plasticity and neurodegenerative disease. J Signal Transduct 2012.","DOI":"10.1155\/2012\/649079"},{"key":"10.1016\/j.neuroscience.2024.11.078_b0150","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.3389\/fphar.2021.656561","article-title":"The CNS-penetrant soluble guanylate cyclase stimulator CY6463 reveals its therapeutic potential in neurodegenerative diseases","volume":"12","author":"Correia","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.neuroscience.2024.11.078_b0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12974-021-02275-z","article-title":"The CNS-penetrant soluble guanylate cyclase stimulator CYR119 attenuates markers of inflammation in the central nervous system","volume":"18","author":"Correia","year":"2021","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.neuroscience.2024.11.078_b0160","first-page":"729","article-title":"Epitope determines efficacy of therapeutic anti-Tau antibodies in a functional assay with human Alzheimer Tau","volume":"136","author":"Courade","year":"2018","journal-title":"ActaNeuropathol"},{"issue":"1","key":"10.1016\/j.neuroscience.2024.11.078_b0165","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/archneurol.2011.233","article-title":"Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial","volume":"69","author":"Craft","year":"2012","journal-title":"Arch. Neurol."},{"issue":"9","key":"10.1016\/j.neuroscience.2024.11.078_b0170","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1001\/jamaneurol.2020.1840","article-title":"Safety, efficacy, and feasibility of intranasal insulin for the treatment of mild cognitive impairment and Alzheimer disease dementia: a randomized clinical trial","volume":"77","author":"Craft","year":"2020","journal-title":"JAMA Neurol."},{"issue":"1","key":"10.1016\/j.neuroscience.2024.11.078_b0175","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41582-019-0284-z","article-title":"Cannabinoids and the expanded endocannabinoid system in neurological disorders","volume":"16","author":"Cristino","year":"2020","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.neuroscience.2024.11.078_b0180","article-title":"Noradrenergic intervention in","volume":"67","author":"Crook","year":"1992","journal-title":"Psychopharmacol Bull"},{"issue":"2","key":"10.1016\/j.neuroscience.2024.11.078_b0185","first-page":"250","article-title":"Protection from Amyloid \u03b2 Peptide\u2013Induced Memory, Biochemical, and Morphological Deficits by a Phosphodiesterase-4D Allosteric Inhibitor","volume":"371","author":"Cui","year":"2019","journal-title":"J PharmacolExpTher"},{"issue":"12","key":"10.1016\/j.neuroscience.2024.11.078_b0190","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1001\/jama.2015.10214","article-title":"Effect of dextromethorphan-quinidine on agitation in patients with Alzheimer disease dementia: a randomized clinical trial","volume":"314","author":"Cummings","year":"2015","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.neuroscience.2024.11.078_b0195","article-title":"Alzheimer's disease drug development pipeline: 2023","volume":"9","author":"Cummings","year":"2023","journal-title":"Alzheimer's & Dementia: Translational Research & Clinical Interventions"},{"issue":"3","key":"10.1016\/j.neuroscience.2024.11.078_b0200","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jalz.2013.12.003","article-title":"The MultiTEP platform\u2013based Alzheimer's disease epitope vaccine activates a broad repertoire of T helper cells in nonhuman primates","volume":"10","author":"Davtyan","year":"2014","journal-title":"Alzheimers Dement."},{"issue":"6","key":"10.1016\/j.neuroscience.2024.11.078_b0205","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1073\/pnas.0809158106","article-title":"Protection of synapses against Alzheimer's-linked toxins: insulin signaling prevents the pathogenic binding of A\u03b2 oligomers","volume":"106","author":"De Felice","year":"2009","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.neuroscience.2024.11.078_b0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-019-0546-4","article-title":"Targeting soluble tumor necrosis factor as a potential intervention to lower risk for late-onset Alzheimer\u2019s disease associated with obesity, metabolic syndrome, and type 2 diabetes","volume":"12","author":"De Sousa Rodrigues","year":"2020","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"10.1016\/j.neuroscience.2024.11.078_b0220","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2174\/1567205014666170117141330","article-title":"Poor safety and tolerability hamper reaching a potentially therapeutic dose in the use of thalidomide for Alzheimer\u2019s disease: results from a double-blind, placebo-controlled trial","volume":"14","author":"Decourt","year":"2017","journal-title":"Curr Alzheimer Res"},{"key":"10.1016\/j.neuroscience.2024.11.078_b0225","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/OAJCT.S221914","article-title":"MCLENA-1: a phase II clinical trial for the assessment of safety, tolerability, and efficacy of lenalidomide in patients with mild cognitive impairment due to Alzheimer\u2019s disease","volume":"7","author":"Decourt","year":"2020","journal-title":"Open Access J Clin Trials"},{"issue":"1","key":"10.1016\/j.neuroscience.2024.11.078_b0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13024-019-0333-5","article-title":"The neuropathological diagnosis of Alzheimer\u2019s disease","volume":"14","author":"DeTure","year":"2019","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.neuroscience.2024.11.078_b0235","article-title":"Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy","volume":"9(374):eaag0481","author":"DeVos","year":"2017","journal-title":"SciTransl Med"},{"issue":"4","key":"10.1016\/j.neuroscience.2024.11.078_b0240","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease","volume":"370","author":"Doody","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.neuroscience.2024.11.078_b0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0066101","article-title":"Amyloid-\u03b2 protofibrils: size, morphology and synaptotoxicity of an engineered mimic","volume":"8","author":"Dubnovitsky","year":"2013","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.neuroscience.2024.11.078_b0250","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/nm919","article-title":"Glucagon-like peptide-1 receptor is involved in learning and neuroprotection","volume":"9","author":"During","year":"2003","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.neuroscience.2024.11.078_b0255","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1038\/s41591-022-01919-8","article-title":"Pepinemab antibody blockade of SEMA4D in early Huntington\u2019s disease: a randomized, placebo-controlled, phase 2 trial","volume":"28","author":"Feigin","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.neuroscience.2024.11.078_b0260","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1080\/19420862.2015.1102813","article-title":"Generation and preclinical characterization of an antibody specific for SEMA4D","volume":"8","author":"Fisher","year":"2016","journal-title":"MAbs"},{"issue":"6212","key":"10.1016\/j.neuroscience.2024.11.078_b0265","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1126\/science.1261754","article-title":"Nucleoside reverse transcriptase inhibitors possess intrinsic anti-inflammatory activity","volume":"346","author":"Fowler","year":"2014","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.neuroscience.2024.11.078_b0270","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/gps.1949","article-title":"Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis","volume":"23","author":"Gauthier","year":"2008","journal-title":"Int J Geriatr Psychiatry"},{"issue":"10062","key":"10.1016\/j.neuroscience.2024.11.078_b0275","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1016\/S0140-6736(16)31275-2","article-title":"Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial","volume":"388","author":"Gauthier","year":"2016","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.neuroscience.2024.11.078_b0280","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/cns.12596","article-title":"Cysteinyl leukotrienes and their receptors: emerging therapeutic targets in central nervous system disorders","volume":"22","author":"Ghosh","year":"2016","journal-title":"CNS NeurosciTher"},{"issue":"18","key":"10.1016\/j.neuroscience.2024.11.078_b0285","doi-asserted-by":"crossref","first-page":"10417","DOI":"10.1073\/pnas.1834302100","article-title":"Alzheimer's disease-affected brain: presence of oligomeric A\u03b2 ligands (ADDLs) suggests a molecular basis for reversible memory loss","volume":"100","author":"Gong","year":"2003","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.neuroscience.2024.11.078_b0290","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.neuropharm.2013.11.025","article-title":"Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy","volume":"79","author":"Graham","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuroscience.2024.11.078_b0295","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.trci.2018.11.001","article-title":"A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer's disease","volume":"5","author":"Grundman","year":"2019","journal-title":"Alzheimers Dement (n y)"},{"key":"10.1016\/j.neuroscience.2024.11.078_b0300","doi-asserted-by":"crossref","unstructured":"Gueorguieva I, Willis BA, Chua L, Chow K, Ernest CS, Shcherbinin S, Ardayfio P, Mullins GR, Sims JR (2023) Donanemab population pharmacokinetics, amyloid plaque reduction, and safety in participants with Alzheimer's disease. Clinical Pharmacology & Therapeutics. Feb 18.","DOI":"10.1002\/cpt.2875"},{"issue":"3","key":"10.1016\/j.neuroscience.2024.11.078_b0305","doi-asserted-by":"crossref","first-page":"967","DOI":"10.3233\/JAD-200134","article-title":"Safety, tolerability, and pharmacokinetics of crenezumab in patients with mild-to-moderate Alzheimer\u2019s disease treated with escalating doses for up to 133 weeks","volume":"76","author":"Guthrie","year":"2020","journal-title":"J. Alzheimers Dis."},{"issue":"3","key":"10.1016\/j.neuroscience.2024.11.078_b0310","doi-asserted-by":"crossref","first-page":"967","DOI":"10.3233\/JAD-200134","article-title":"Safety, tolerability, and pharmacokinetics of crenezumab in patients with mild-to-moderate Alzheimer\u2019s disease treated with escalating doses for up to 133 weeks","volume":"76","author":"Guthrie","year":"2020","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.neuroscience.2024.11.078_b0315","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.celrep.2017.06.023","article-title":"Silent allosteric modulation of mGluR5 maintains glutamate signaling while rescuing Alzheimer\u2019s mouse phenotypes","volume":"20","author":"Haas","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.neuroscience.2024.11.078_b0320","unstructured":"Haase N, Herse F, Spallek B, Haase H, Wallukat G, Qadri F, Szij\u00e1rt\u00f3 IA, Rohm I, Yilmaz A, Warrington JP, Gollasch M. Vasoactivity of the Alzheimer \u03b2-Amyloid Peptides is Mediated by an Activation of the \u03b11-Adrenoreceptor."},{"issue":"21","key":"10.1016\/j.neuroscience.2024.11.078_b0325","doi-asserted-by":"crossref","first-page":"11780","DOI":"10.1073\/pnas.93.21.11780","article-title":"Human CD100, a novel leukocyte semaphorin that promotes B-cell aggregation and differentiation","volume":"93","author":"Hall","year":"1996","journal-title":"Proc Natl AcadSci USA"},{"issue":"9","key":"10.1016\/j.neuroscience.2024.11.078_b0330","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/j.celrep.2016.04.077","article-title":"Chronic pharmacological mGluR5 inhibition prevents cognitive impairment and reduces pathogenesis in an Alzheimer disease mouse model","volume":"15","author":"Hamilton","year":"2016","journal-title":"Cell Rep"},{"issue":"1","key":"10.1016\/j.neuroscience.2024.11.078_b0335","article-title":"A precision medicine framework using artificial intelligence for the identification and confirmation of genomic biomarkers of response to an Alzheimer's disease therapy: analysis of the blarcamesine (ANAVEX2\u201073) Phase 2a clinical study","volume":"6","author":"Hampel","year":"2020","journal-title":"Alzheimers Dement."},{"issue":"12","key":"10.1016\/j.neuroscience.2024.11.078_b0340","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.4103\/1673-5374.339472","article-title":"A new age in understanding adult hippocampal neurogenesis in Alzheimer\u2019s disease","volume":"17","author":"Hanspal","year":"2022","journal-title":"Neural Regen Res"},{"issue":"1","key":"10.1016\/j.neuroscience.2024.11.078_b0345","article-title":"Safety, tolerability, and pharmacokinetics of allopregnanolone as a regenerative therapeutic for Alzheimer's disease: a single and multiple ascending dose phase 1b\/2a clinical trial","volume":"6","author":"Hernandez","year":"2020","journal-title":"Alzheimers Dement (n y)"},{"issue":"3","key":"10.1016\/j.neuroscience.2024.11.078_b0350","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/alz.12035","article-title":"Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial","volume":"16","author":"Herring","year":"2020","journal-title":"Alzheimers Dement."},{"issue":"11","key":"10.1016\/j.neuroscience.2024.11.078_b0355","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.jagp.2019.05.002","article-title":"Randomized placebo-controlled trial of nabilone for agitation in Alzheimer's disease","volume":"27","author":"Herrmann","year":"2019","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/j.neuroscience.2024.11.078_b0360","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s40262-017-0608-3","article-title":"Clinical pharmacokinetics and safety of ALZ-801, a novel prodrug of tramiprosate in development for the treatment of Alzheimer\u2019s disease","volume":"57","author":"Hey","year":"2018","journal-title":"Clin. Pharmacokinet."},{"issue":"16","key":"10.1016\/j.neuroscience.2024.11.078_b0365","first-page":"13966","article-title":"Sequence-independent control of peptide conformation in liposomal vaccines for targeting protein misfolding diseases","volume":"286","author":"Hickman","year":"2011","journal-title":"J BiolChem"},{"issue":"1","key":"10.1016\/j.neuroscience.2024.11.078_b0370","first-page":"252","article-title":"A novel neurotrophic agent, T-817MA [1-{3-[2-(1-benzothiophen-5-yl) ethoxy] propyl}-3-azetidinol maleate], attenuates amyloid-\u03b2-induced neurotoxicity and promotes neurite outgrowth in rat cultured central nervous system neurons","volume":"314","author":"Hirata","year":"2005","journal-title":"J PharmacolExpTher"},{"key":"10.1016\/j.neuroscience.2024.11.078_b0375","first-page":"19","article-title":"Diffusible, highly bioactive oligomers represent a critical minority of soluble A\u03b2 in Alzheimer\u2019s disease brain","volume":"136","author":"Hong","year":"2018","journal-title":"Actaneuropathologica"},{"issue":"4","key":"10.1016\/j.neuroscience.2024.11.078_b0380","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa1705971","article-title":"Trial of solanezumab for mild dementia due to Alzheimer\u2019s disease","volume":"378","author":"Honig","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neuroscience.2024.11.078_b0385","doi-asserted-by":"crossref","unstructured":"Horie K, Takahashi E, Aoyama M, Nakatani Y, Roberts M, Staddon J, de Silva R, Koyama A (2019) P4\u2010696: QUANTIFICATION OF THE TAU MICROTUBULE BINDING REGION (MTBR) IN CEREBROSPINAL FLUID AND SUBSEQUENT VALIDATION OF TARGET ENGAGEMENT ASSAY FOR E2814, A NOVEL ANTI\u2010TAU THERAPEUTIC ANTIBODY. Alzheimer's & Dementia 15:P1598-9.","DOI":"10.1016\/j.jalz.2019.09.060"},{"key":"10.1016\/j.neuroscience.2024.11.078_b0390","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.neuropharm.2014.01.011","article-title":"Montelukast targeting the cysteinyl leukotriene receptor 1 ameliorates A\u03b21-42-induced memory impairment and neuroinflammatory and apoptotic responses in mice","volume":"79","author":"Hu","year":"2014","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.neuroscience.2024.11.078_b0395","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.3233\/JAD-215511","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of the positive modulator of HGF\/MET, fosgonimeton, in healthy volunteers and subjects with Alzheimer\u2019s disease: Randomized, placebo-controlled, double-blind, phase I clinical trial","volume":"86","author":"Hua","year":"2022","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.neuroscience.2024.11.078_b0400","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12929-019-0609-7","article-title":"Clinical trials of new drugs for Alzheimer disease","volume":"27","author":"Huang","year":"2020","journal-title":"J. Biomed. Sci."},{"issue":"1","key":"10.1016\/j.neuroscience.2024.11.078_b0405","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41467-019-14082-5","article-title":"The epichaperome is a mediator of toxic hippocampal stress and leads to protein connectivity-based dysfunction","volume":"11","author":"Inda","year":"2020","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.neuroscience.2024.11.078_b0410","doi-asserted-by":"crossref","first-page":"41226","DOI":"10.4088\/JCP.21m14345","article-title":"Efficacy and safety of AXS-05 (dextromethorphan-bupropion) in patients with major depressive disorder: a phase 3 randomized clinical trial (GEMINI)","volume":"83","author":"Iosifescu","year":"2022","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.neuroscience.2024.11.078_b0415","doi-asserted-by":"crossref","first-page":"202","DOI":"10.3389\/fnagi.2014.00202","article-title":"Herpes simplex virus type 1 and Alzheimer\u2019s disease: increasing evidence for a major role of the virus","volume":"6","author":"Itzhaki","year":"2014","journal-title":"Front Aging Neurosci"},{"issue":"2","key":"10.1016\/j.neuroscience.2024.11.078_b0420","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3233\/JAD-180266","article-title":"Herpes viruses and senile dementia: first population evidence for a causal link","volume":"64","author":"Itzhaki","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.neuroscience.2024.11.078_b0425","article-title":"In vivo and neuropathology data support locus coeruleus integrity as an indicator of Alzheimer\u2019s disease pathology and cognitive decline","volume":"13(612):eabj2511","author":"Jacobs","year":"2021","journal-title":"SciTransl Med"},{"key":"10.1016\/j.neuroscience.2024.11.078_b0430","first-page":"1","article-title":"Current Insights of Nanocarrier-Mediated Gene Therapeutics to Treat Potential Impairment of Amyloid Beta Protein and Tau Protein in Alzheimer\u2019s Disease","volume":"13","author":"Jain","year":"2023","journal-title":"Mol. Neurobiol."},{"issue":"1","key":"10.1016\/j.neuroscience.2024.11.078_b0435","first-page":"61","volume":"6","author":"Johnson","year":"2006","journal-title":"Mechanism of Action of Memantine. Curropinpharmacol"},{"issue":"5","key":"10.1016\/j.neuroscience.2024.11.078_b0440","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/ana.26511","article-title":"Amyloid-Related Imaging Abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease","volume":"92","author":"Joseph-Mathurin","year":"2022","journal-title":"Ann. Neurol."},{"issue":"1","key":"10.1016\/j.neuroscience.2024.11.078_b0445","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3233\/ADR-200250","article-title":"Porphyromonasgingivalis is a strong risk factor for Alzheimer\u2019s disease","volume":"4","author":"Kanagasingam","year":"2020","journal-title":"J Alzheimers Dis Rep"},{"issue":"4","key":"10.1016\/j.neuroscience.2024.11.078_b0450","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.3233\/JAD-161118","article-title":"Therapeutics of neurotransmitters in Alzheimer\u2019s disease","volume":"57","author":"Kandimalla","year":"2017","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"10.1016\/j.neuroscience.2024.11.078_b0455","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.neurobiolaging.2012.09.010","article-title":"Prazosin, an \u03b11-adrenoceptor antagonist, prevents memory deterioration in the APP23 transgenic mouse model of Alzheimer's disease","volume":"34","author":"Katsouri","year":"2013","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.neuroscience.2024.11.078_b0460","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2019.172796","article-title":"ANAVEX\u00ae 2-73 (blarcamesine), a Sigma-1 receptor agonist, ameliorates neurologic impairments in a mouse model of Rett syndrome","volume":"187","author":"Kaufmann","year":"2019","journal-title":"Pharmacol. Biochem. Behav"},{"key":"10.1016\/j.neuroscience.2024.11.078_b0465","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s11062-019-09823-7","article-title":"Altered neurochemistry in Alzheimer\u2019s disease: Targeting neurotransmitter receptor mechanisms and therapeutic strategy","volume":"51","author":"Kaur","year":"2019","journal-title":"Neurophysiology"},{"issue":"1","key":"10.1016\/j.neuroscience.2024.11.078_b0470","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.psym.2017.08.005","article-title":"The association between leukotriene-modifying agents and suicidality: a review of literature","volume":"59","author":"Khalid","year":"2018","journal-title":"Psychosomatics"},{"key":"10.1016\/j.neuroscience.2024.11.078_b0475","doi-asserted-by":"crossref","unstructured":"Khalifeh M, Barreto GE, Sahebkar A (2021) Therapeutic potential of trehalose in neurodegenerative diseases: The knowns and unknowns. Neural Regeneration Research 16(10):2026.","DOI":"10.4103\/1673-5374.308085"},{"issue":"9","key":"10.1016\/j.neuroscience.2024.11.078_b0480","doi-asserted-by":"crossref","first-page":"5744","DOI":"10.1167\/iovs.14-14672","article-title":"HE3286 reduces axonal loss and preserves retinal ganglion cell function in experimental optic neuritis","volume":"55","author":"Khan","year":"2014","journal-title":"Invest Ophthalmol vis Sci"},{"issue":"9","key":"10.1016\/j.neuroscience.2024.11.078_b0485","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1523\/JNEUROSCI.5253-05.2006","article-title":"Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis","volume":"26","author":"Kiaei","year":"2006","journal-title":"J Neurosci"},{"key":"10.1016\/j.neuroscience.2024.11.078_b0490","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.1002281","article-title":"Relationship between adult subventricular neurogenesis and Alzheimer\u2019s disease: Pathologic roles and therapeutic implications","volume":"14","author":"Kim","year":"2022","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"10.1016\/j.neuroscience.2024.11.078_b0495","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-019-0559-z","article-title":"Gantenerumab reduces amyloid-\u03b2 plaques in patients with prodromal to moderate Alzheimer\u2019s disease: a PET substudy interim analysis","volume":"11","author":"Klein","year":"2019","journal-title":"Alzheimers Res. Ther."},{"issue":"3","key":"10.1016\/j.neuroscience.2024.11.078_b0500","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.immuni.2017.08.008","article-title":"The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases","volume":"47","author":"Krasemann","year":"2017","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.neuroscience.2024.11.078_b0505","doi-asserted-by":"crossref","first-page":"572","DOI":"10.18632\/aging.203835","article-title":"Combination of dasatinib and quercetin improves cognitive abilities in aged male Wistar rats, alleviates inflammation and changes hippocampal synaptic plasticity and histone H3 methylation profile","volume":"14","author":"Krzystyniak","year":"2022","journal-title":"Aging (Albany NY)"},{"issue":"6","key":"10.1016\/j.neuroscience.2024.11.078_b0510","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1016\/j.celrep.2016.06.099","article-title":"Antibody-mediated targeting of tau in vivo does not require effector function and microglial engagement","volume":"16","author":"Lee","year":"2016","journal-title":"Cell Rep"},{"key":"10.1016\/j.neuroscience.2024.11.078_b0515","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.REV120.008207","article-title":"The essential elements of Alzheimer\u2019s disease","volume":"296","author":"Lei","year":"2021","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.neuroscience.2024.11.078_b0520","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41582-020-00435-y","article-title":"Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?","volume":"17","author":"Leng","year":"2021","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"10.1016\/j.neuroscience.2024.11.078_b0525","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-016-0181-2","article-title":"Safety and tolerability of BAN2401-a clinical study in Alzheimer\u2019s disease with a protofibril selective A\u03b2 antibody","volume":"8","author":"Logovinsky","year":"2016","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.neuroscience.2024.11.078_b0530","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/B978-0-12-804766-8.00009-1","article-title":"Epidemiology of aging and associated cognitive disorders: Prevalence and incidence of Alzheimer's disease and other dementias","volume":"167","author":"Lopez","year":"2019","journal-title":"Handb. Clin. Neurol."},{"issue":"3","key":"10.1016\/j.neuroscience.2024.11.078_b0535","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.nbd.2009.08.007","article-title":"An amyloid-\u03b2 protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease","volume":"36","author":"Lord","year":"2009","journal-title":"Neurobiol. Dis."},{"issue":"1","key":"10.1016\/j.neuroscience.2024.11.078_b0540","article-title":"Donanemab (LY3002813) dose\u2010escalation study in Alzheimer's disease","volume":"7","author":"Lowe","year":"2021","journal-title":"Alzheimer's & Dementia: Translational Research & Clinical Interventions"},{"issue":"6","key":"10.1016\/j.neuroscience.2024.11.078_b0545","first-page":"1280","article-title":"Asthma treatments and mental health visits after a Food and Drug Administration label change for leukotriene inhibitors","volume":"37","author":"Lu","year":"2015","journal-title":"ClinTher"},{"key":"10.1016\/j.neuroscience.2024.11.078_b0550","doi-asserted-by":"crossref","unstructured":"Lucey BP, Liu H, Toedebusch CD, Freund D, Redrick T, Chahin SL, Mawuenyega KG, Bollinger JG, Ovod V, Barth\u00e9lemy NR, Bateman RJ (2023) Suvorexant acutely decreases tau phosphorylation and A\u03b2 in the human CNS. Ann Neurol. Mar 10.","DOI":"10.1002\/ana.26641"},{"key":"10.1016\/j.neuroscience.2024.11.078_b0555","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.neuroscience.2011.04.010","article-title":"Neurosteroid and GABA-A receptor alterations in Alzheimer's disease, Parkinson's disease and multiple sclerosis","volume":"191","author":"Luchetti","year":"2011","journal-title":"Neuroscience"},{"issue":"2","key":"10.1016\/j.neuroscience.2024.11.078_b0560","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3233\/JAD-150493","article-title":"Metformin in amnestic mild cognitive impairment: results of a pilot randomized placebo controlled clinical trial","volume":"51","author":"Luchsinger","year":"2016","journal-title":"J. Alzheimers Dis."},{"issue":"8","key":"10.1016\/j.neuroscience.2024.11.078_b0565","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3390\/bios11080255","article-title":"Optical imaging of beta-amyloid plaques in Alzheimer\u2019s disease","volume":"11","author":"Luo","year":"2021","journal-title":"Biosensors"},{"issue":"3","key":"10.1016\/j.neuroscience.2024.11.078_b0570","doi-asserted-by":"crossref","DOI":"10.4155\/fso.15.9","article-title":"The role and therapeutic targeting of \u03b1-, \u03b2-and \u03b3-secretase in Alzheimer's disease","volume":"1","author":"MacLeod","year":"2015","journal-title":"Future Sci. OA"},{"key":"10.1016\/j.neuroscience.2024.11.078_b0575","article-title":"How neurons die in Alzheimer's disease: Implications for neuroinflammation","volume":"75","author":"Mangalmurti","year":"2022","journal-title":"CurrOpinNeurobiol"},{"issue":"1","key":"10.1016\/j.neuroscience.2024.11.078_b0580","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1038\/s41467-018-03421-7","article-title":"Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults","volume":"9","author":"Martens","year":"2018","journal-title":"Nat Commun"},{"issue":"3","key":"10.1016\/j.neuroscience.2024.11.078_b0585","doi-asserted-by":"crossref","first-page":"196","DOI":"10.2174\/157488911796958020","article-title":"Pharmacological strategies against glucocorticoid-mediated brain damage during chronic disorders","volume":"6","author":"Martocchia","year":"2011","journal-title":"Recent Patents on CNS Drug Discovery (discontinued)"},{"issue":"1","key":"10.1016\/j.neuroscience.2024.11.078_b0590","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3390\/cells12010131","article-title":"Pharmacotherapy evolution in Alzheimer\u2019s disease: current framework and relevant directions","volume":"12","author":"Miculas","year":"2022","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.neuroscience.2024.11.078_b0595","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1530\/JOE-17-0263","article-title":"Metabolic and neuroprotective effects of dapagliflozin and liraglutide in diabetic mice","volume":"234","author":"Millar","year":"2017","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.neuroscience.2024.11.078_b0600","doi-asserted-by":"crossref","DOI":"10.3233\/JAD-220871","article-title":"The case for a novel therapeutic approach to dementia: Small molecule hepatocyte growth factor (HGF\/MET) positive modulators","author":"Moebius","year":"2023","journal-title":"J Alzheimers Dis (Preprint):1-2."},{"key":"10.1016\/j.neuroscience.2024.11.078_b0605","doi-asserted-by":"crossref","DOI":"10.1002\/alz.045720","volume":"16","author":"Molina","year":"2020","journal-title":"Alzheimers Dement."},{"issue":"14","key":"10.1016\/j.neuroscience.2024.11.078_b0610","doi-asserted-by":"crossref","first-page":"e1391","DOI":"10.1212\/WNL.0000000000207663","article-title":"Randomized phase II study of the safety and efficacy of semorinemab in participants with mild-to-moderate Alzheimer disease: Lauriet","volume":"101","author":"Monteiro","year":"2023","journal-title":"Neurology"},{"issue":"16","key":"10.1016\/j.neuroscience.2024.11.078_b0615","first-page":"9305","article-title":"Symptomatic and disease-modifying therapy pipeline for Alzheimer\u2019s disease: Towards a personalized polypharmacology patient-centered approach","volume":"23","author":"Morat\u00f3","year":"2022","journal-title":"Int J MolSci"},{"issue":"8","key":"10.1016\/j.neuroscience.2024.11.078_b0620","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1089\/ars.2017.7493","article-title":"Could Conservative Iron Chelation Lead to Neuroprotection in Amyotrophic Lateral Sclerosis?","volume":"29","author":"Moreau","year":"2018","journal-title":"Antioxid Redox Signal"},{"issue":"5","key":"10.1016\/j.neuroscience.2024.11.078_b0625","doi-asserted-by":"crossref","first-page":"e2124","DOI":"10.1371\/journal.pone.0002124","article-title":"Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine\u2014a novel immunotherapeutic strategy","volume":"3","author":"Movsesyan","year":"2008","journal-title":"PLoS One"},{"issue":"23","key":"10.1016\/j.neuroscience.2024.11.078_b0630","doi-asserted-by":"crossref","first-page":"9810","DOI":"10.1073\/pnas.0703137104","article-title":"Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice","volume":"104","author":"Muhs","year":"2007","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.neuroscience.2024.11.078_b0635","first-page":"1","article-title":"Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer\u2019s disease: a phase 1b, randomized, placebo-controlled trial","volume":"24","author":"Mummery","year":"2023","journal-title":"Nat Med"},{"issue":"33","key":"10.1016\/j.neuroscience.2024.11.078_b0640","first-page":"20967","article-title":"Macrophage colony-stimulating factor augments \u03b2-amyloid-induced interleukin-1, interleukin-6, and nitric oxide production by microglial cells","volume":"273","author":"Murphy","year":"1998","journal-title":"J BiolChem"},{"key":"10.1016\/j.neuroscience.2024.11.078_b0645","first-page":"951","article-title":"Youssef NA (2010) Allopregnanolone levels are reduced in temporal cortex in patients with Alzheimer's disease compared to cognitively intact control subjects","volume":"8","author":"Naylor","year":"1801","journal-title":"BiochimBiophysActa"},{"issue":"2","key":"10.1016\/j.neuroscience.2024.11.078_b0650","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1684\/epd.2021.1406","article-title":"Epilepsy in neurodegenerative diseases","volume":"24","author":"Neri","year":"2022","journal-title":"Epileptic Disord."},{"issue":"2","key":"10.1016\/j.neuroscience.2024.11.078_b0655","first-page":"195","volume":"11","author":"NikolacPerkovic","year":"2021","journal-title":"Epigenetics of Alzheimer\u2019s Disease. Biomolecules"},{"issue":"9","key":"10.1016\/j.neuroscience.2024.11.078_b0660","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/nn0901-887","article-title":"The'Arctic'APP mutation (E693G) causes Alzheimer's disease by enhanced A\u03b2 protofibril formation","volume":"4","author":"Nilsberth","year":"2001","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuroscience.2024.11.078_b0665","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s40262-013-0038-9","article-title":"Pharmacodynamics, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer\u2019s disease","volume":"52","author":"Noetzli","year":"2013","journal-title":"Clin. Pharmacokinet."},{"issue":"1","key":"10.1016\/j.neuroscience.2024.11.078_b0670","article-title":"Treatment with glucagon\u2010like peptide\u20101 receptor agonists and incidence of dementia: Data from pooled double\u2010blind randomized controlled trials and nationwide disease and prescription registers","volume":"8","author":"N\u00f8rgaard","year":"2022","journal-title":"Alzheimers Dement."},{"issue":"3","key":"10.1016\/j.neuroscience.2024.11.078_b0675","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1128\/IAI.01038-08","article-title":"PorphyromonasgingivalisRgpA-Kgp proteinase-adhesin complexes penetrate gingival tissue and induce proinflammatory cytokines or apoptosis in a concentration-dependent manner","volume":"77","author":"O'Brien-Simpson","year":"2009","journal-title":"Infect Immun"},{"issue":"2","key":"10.1016\/j.neuroscience.2024.11.078_b0680","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1111\/bph.14862","article-title":"Pharmacological targeting of \u03b22\u2010adrenoceptors is neuroprotective in the LPS inflammatory rat model of Parkinson's disease","volume":"177","author":"O'Neill","year":"2020","journal-title":"Br J Pharmacol"},{"issue":"5","key":"10.1016\/j.neuroscience.2024.11.078_b0685","first-page":"524","volume":"9","author":"Onyango","year":"2021","journal-title":"Neuroinflammation in Alzheimer\u2019s Disease. Biomedicines"},{"issue":"2","key":"10.1016\/j.neuroscience.2024.11.078_b0690","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1001\/archneurol.2011.1538","article-title":"Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab","volume":"69","author":"Ostrowitzki","year":"2012","journal-title":"Arch. Neurol."},{"issue":"12","key":"10.1016\/j.neuroscience.2024.11.078_b0695","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.jagp.2021.01.015","article-title":"Cannabinoids for agitation in Alzheimer's disease","volume":"29","author":"Outen","year":"2021","journal-title":"Am J Geriatr Psychiatry"},{"key":"10.1016\/j.neuroscience.2024.11.078_b0700","doi-asserted-by":"crossref","unstructured":"Oxford AE, Stewart ES, Rohn TT (2020) Clinical trials in Alzheimer\u2019s disease: a hurdle in the path of remedy. International Journal of Alzheimer\u2019s Disease 2020.","DOI":"10.1155\/2020\/5380346"},{"issue":"3","key":"10.1016\/j.neuroscience.2024.11.078_b0705","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3390\/cells10030545","article-title":"Daratumumab in the treatment of light-chain (AL) amyloidosis","volume":"10","author":"Palladini","year":"2021","journal-title":"Cells"},{"issue":"46","key":"10.1016\/j.neuroscience.2024.11.078_b0710","doi-asserted-by":"crossref","first-page":"12721","DOI":"10.1523\/JNEUROSCI.3201-07.2007","article-title":"Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble\/oligomeric A\u03b2 species in amyloid precursor protein transgenic mice","volume":"27","author":"Petrushina","year":"2007","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/j.neuroscience.2024.11.078_b0715","first-page":"45","article-title":"Plasma cortisol, brain amyloid-\u03b2, and cognitive decline in preclinical Alzheimer\u2019s disease: a 6-year prospective cohort study","volume":"2","author":"Pietrzak","year":"2017","journal-title":"Biol. Psychiatry: Cognit. Neurosci. Neuroimaging"},{"issue":"3","key":"10.1016\/j.neuroscience.2024.11.078_b0720","first-page":"439","article-title":"Clinical trials in predementia stages of Alzheimer disease","volume":"97","author":"Pillai","year":"2013","journal-title":"Medical Clinics"},{"issue":"1","key":"10.1016\/j.neuroscience.2024.11.078_b0725","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.clinthera.2019.11.015","article-title":"A phase I study to assess the effect of speed of injection on pain, tolerability, and pharmacokinetics after high-volume subcutaneous administration of gantenerumab in healthy volunteers","volume":"42","author":"Portron","year":"2020","journal-title":"Clin. Ther."},{"issue":"6","key":"10.1016\/j.neuroscience.2024.11.078_b0730","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1001\/jamaneurol.2022.0983","article-title":"Safety, tolerability, and immunogenicity of the ACI-24 vaccine in adults with Down syndrome: a phase 1b randomized clinical trial","volume":"79","author":"Rafii","year":"2022","journal-title":"JAMA Neurol."},{"issue":"6","key":"10.1016\/j.neuroscience.2024.11.078_b0735","first-page":"3146","article-title":"Sovateltide mediated endothelin B receptors agonism and curbing neurological disorders","volume":"23","author":"Ranjan","year":"2022","journal-title":"Int J MolSci"},{"issue":"7","key":"10.1016\/j.neuroscience.2024.11.078_b0740","doi-asserted-by":"crossref","first-page":"3580","DOI":"10.1021\/acs.jproteome.1c00180","article-title":"Levetiracetam treatment normalizes levels of presynaptic endocytosis machinery and restores nonamyloidogenic APP processing in App knock-in mice","volume":"20","author":"Rao","year":"2021","journal-title":"J Proteome Res"},{"issue":"04","key":"10.1016\/j.neuroscience.2024.11.078_b0745","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2217\/nmt-2021-0022","article-title":"NM101 Phase III study of NE3107 in Alzheimer\u2019s disease: Rationale, design and therapeutic modulation of neuroinflammation and insulin resistance","volume":"11","author":"Reading","year":"2021","journal-title":"Neurodegener Dis Manag"},{"issue":"1","key":"10.1016\/j.neuroscience.2024.11.078_b0750","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1073\/pnas.2635903100","article-title":"Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia","volume":"101","author":"Reiman","year":"2004","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"9","key":"10.1016\/j.neuroscience.2024.11.078_b0755","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1021\/acsmedchemlett.1c00048","article-title":"Discovery of investigational drug CT1812, an antagonist of the sigma-2 receptor complex for Alzheimer\u2019s disease","volume":"12","author":"Rishton","year":"2021","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.neuroscience.2024.11.078_b0760","first-page":"1","article-title":"Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer\u2019s disease","volume":"8","author":"Roberts","year":"2020","journal-title":"ActaNeuropatholCommun"},{"issue":"8","key":"10.1016\/j.neuroscience.2024.11.078_b0765","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.4103\/1673-5374.332127","article-title":"Amyloid-beta peptide and tau protein crosstalk in Alzheimer\u2019s disease","volume":"17","author":"Roda","year":"2022","journal-title":"Neural Regen. Res."},{"issue":"1","key":"10.1016\/j.neuroscience.2024.11.078_b0770","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40035-021-00258-x","article-title":"Novel multivalent design of a monoclonal antibody improves binding strength to soluble aggregates of amyloid beta","volume":"10","author":"Rofo","year":"2021","journal-title":"Translational Neurodegeneration"},{"issue":"11","key":"10.1016\/j.neuroscience.2024.11.078_b0775","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/j.jagp.2019.05.014","article-title":"Tetrahydrocannabinol Has Potential for Treating Agitation in Alzheimer's Disease","volume":"27","author":"Rosenberg","year":"2019","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.neuroscience.2024.11.078_b0780","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ebiom.2017.09.004","article-title":"Potent and selective BACE-1 peptide inhibitors lower brain A\u03b2 levels mediated by brain shuttle transport","volume":"24","author":"Ruderisch","year":"2017","journal-title":"EBioMedicine"},{"key":"10.1016\/j.neuroscience.2024.11.078_b0785","article-title":"Investigating the safety and efficacy of nabilone for the treatment of agitation in patients with moderate-to-severe Alzheimer's disease: study protocol for a cross-over randomized controlled trial","volume":"15","author":"Ruthirakuhan","year":"2019","journal-title":"ContempClin Trials Commun."},{"issue":"35","key":"10.1016\/j.neuroscience.2024.11.078_b0790","doi-asserted-by":"crossref","first-page":"15595","DOI":"10.1073\/pnas.1001740107","article-title":"Stabilization of neurotoxic Alzheimer amyloid-\u03b2 oligomers by protein engineering","volume":"107","author":"Sandberg","year":"2010","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.neuroscience.2024.11.078_b0795","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-022-01141-1","article-title":"A\u03b242 oligomer-specific antibody ALZ-201 reduces the neurotoxicity of Alzheimer\u2019s disease brain extracts","volume":"14","author":"Sandberg","year":"2022","journal-title":"Alzheimers Res. Ther."},{"issue":"5","key":"10.1016\/j.neuroscience.2024.11.078_b0800","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1097\/00000542-200205000-00005","article-title":"Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: efficacy and dose-response trials","volume":"96","author":"Sang","year":"2002","journal-title":"J. Am. Soc. Anesthesiol."},{"key":"10.1016\/j.neuroscience.2024.11.078_b0805","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.taap.2017.08.005","article-title":"SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats","volume":"333","author":"Sa-Nguanmoo","year":"2017","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"1","key":"10.1016\/j.neuroscience.2024.11.078_b0810","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trci.2016.01.001","article-title":"Design of a Bayesian adaptive phase 2 proof-of-concept trial for BAN2401, a putative disease-modifying monoclonal antibody for the treatment of Alzheimer's disease","volume":"2","author":"Satlin","year":"2016","journal-title":"Alzheimer's & Dementia: Translational Research & Clinical Interventions"},{"issue":"11","key":"10.1016\/j.neuroscience.2024.11.078_b0815","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1001\/jamaneurol.2019.1868","article-title":"Safety and efficacy of edonerpic maleate for patients with mild to moderate Alzheimer disease: a phase 2 randomized clinical trial","volume":"76","author":"Schneider","year":"2019","journal-title":"JAMA Neurol"},{"issue":"6","key":"10.1016\/j.neuroscience.2024.11.078_b0820","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer's disease at 25 years","volume":"8","author":"Selkoe","year":"2016","journal-title":"EMBO Mol. Med."},{"issue":"7618","key":"10.1016\/j.neuroscience.2024.11.078_b0825","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.neuroscience.2024.11.078_b0830","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.3390\/antiox10081231","article-title":"Linking oxidative stress and proteinopathy in Alzheimer\u2019s disease","volume":"10","author":"Sharma","year":"2021","journal-title":"Antioxidants"},{"issue":"4","key":"10.1016\/j.neuroscience.2024.11.078_b0835","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1111\/j.1471-4159.1986.tb00753.x","article-title":"Biochemical characterization of \u03b1\u2010adrenergic receptors in human brain and changes in Alzheimer\u2010type dementia","volume":"47","author":"Shimohama","year":"1986","journal-title":"J. Neurochem."},{"issue":"1","key":"10.1016\/j.neuroscience.2024.11.078_b0840","first-page":"19","article-title":"ACU193, a monoclonal antibody that selectively binds soluble A\u03b2 oligomers: development rationale, Phase 1 trial design, and clinical development plan","volume":"10","author":"Siemers","year":"2023","journal-title":"J. Prev. Alzheimers Dis."},{"issue":"11","key":"10.1016\/j.neuroscience.2024.11.078_b0845","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1212\/WNL.57.11.2108","article-title":"Cannabinoids reduce levodopa-induced dyskinesia in Parkinson\u2019s disease: a pilot study","volume":"57","author":"Sieradzan","year":"2001","journal-title":"Neurology"},{"issue":"07","key":"10.1016\/j.neuroscience.2024.11.078_b0850","first-page":"132","article-title":"An investigation into Alzheimer's disease, its current treatments, biomarkers, and risk factors","volume":"12","author":"Srivastav","year":"2023","journal-title":"Int. J. Enhanc. Res. Sci. Technol. Eng"},{"issue":"5641","key":"10.1016\/j.neuroscience.2024.11.078_b0855","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1126\/science.1081297","article-title":"Inactivation of TNF signaling by rationally designed dominant-negative TNF variants","volume":"301","author":"Steed","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.neuroscience.2024.11.078_b0860","unstructured":"https:\/\/synapse.patsnap.com\/drug\/48a762f3b44046869de812196b4a44c0."},{"issue":"7","key":"10.1016\/j.neuroscience.2024.11.078_b0865","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1176\/appi.ajp.21080800","article-title":"Effect of AXS-05 (dextromethorphan-bupropion) in major depressive disorder: a randomized double-blind controlled trial","volume":"179","author":"Tabuteau","year":"2022","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.neuroscience.2024.11.078_b0870","first-page":"11","article-title":"Prazosin for the management of behavioural and psychological symptoms of dementia. Drugs","author":"Tampi","year":"2022","journal-title":"Context"},{"key":"10.1016\/j.neuroscience.2024.11.078_b0875","doi-asserted-by":"crossref","unstructured":"Thal DR, et al (2022) The central role of tau in Alzheimer\u2019s disease: From neurofibrillary tangle maturation to the induction of cell death. Brain Research Bulletin. Oct 13.","DOI":"10.1016\/j.brainresbull.2022.10.006"},{"issue":"8","key":"10.1016\/j.neuroscience.2024.11.078_b0880","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0072301","article-title":"Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau. P301L mice that model tauopathy","volume":"8","author":"Theunis","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.neuroscience.2024.11.078_b0885","doi-asserted-by":"crossref","unstructured":"Tolar M, Abushakra S, Sabbagh M (2019) The path forward in Alzheimer's disease therapeutics: Reevaluating the amyloid cascade hypothesis. Alzheimer's & Dementia. Nov 6.","DOI":"10.1016\/j.jalz.2019.09.075"},{"issue":"1","key":"10.1016\/j.neuroscience.2024.11.078_b0890","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3233\/JAD-151013","article-title":"T3D-959: A multi-faceted disease remedial drug candidate for the treatment of Alzheimer\u2019s disease","volume":"51","author":"Tong","year":"2016","journal-title":"J. Alzheimers Dis."},{"issue":"5","key":"10.1016\/j.neuroscience.2024.11.078_b0895","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.neuron.2013.06.036","article-title":"Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer a\u03b2 oligomer bound to cellular prion protein","volume":"79","author":"Um","year":"2013","journal-title":"Neuron"},{"issue":"5","key":"10.1016\/j.neuroscience.2024.11.078_b0900","doi-asserted-by":"crossref","first-page":"522","DOI":"10.2174\/156720507783018226","article-title":"Novel multifunctional anti-Alzheimer drugs with various CNS neurotransmitter targets and neuroprotective moieties","volume":"4","author":"Van der Schyf","year":"2007","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.neuroscience.2024.11.078_b0905","doi-asserted-by":"crossref","unstructured":"Wang HY, Pei Z, Lee KC, Nikolov B, Doehner T, Puente J, Friedmann N, Burns LH (2023) Simufilam suppresses overactive mTOR and restores its sensitivity to insulin in Alzheimer\u2019s disease patient lymphocytes. Frontiers in Aging 4.","DOI":"10.3389\/fragi.2023.1175601"},{"issue":"1","key":"10.1016\/j.neuroscience.2024.11.078_b0910","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1038\/s41598-018-22979-2","article-title":"An acute functional screen identifies an effective antibody targeting amyloid-\u03b2 oligomers based on calcium imaging","volume":"8","author":"Wang","year":"2018","journal-title":"Sci. Rep."},{"issue":"34","key":"10.1016\/j.neuroscience.2024.11.078_b0915","doi-asserted-by":"crossref","first-page":"31547","DOI":"10.1074\/jbc.M212532200","article-title":"\u03b17 nicotinic acetylcholine receptors mediate \u03b2-amyloid peptide-induced tau protein phosphorylation","volume":"278","author":"Wang","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.neuroscience.2024.11.078_b0920","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200785","article-title":"Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer\u2019s disease model","volume":"217","author":"Wang","year":"2020","journal-title":"J. Exp. Med."},{"issue":"9","key":"10.1016\/j.neuroscience.2024.11.078_b0925","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1097\/JGP.0b013e3181ab8c61","article-title":"Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression","volume":"17","author":"Wang","year":"2009","journal-title":"Am. J. Geriatr. Psychiatry"},{"issue":"14","key":"10.1016\/j.neuroscience.2024.11.078_b0930","doi-asserted-by":"crossref","first-page":"6498","DOI":"10.1073\/pnas.1001422107","article-title":"Allopregnanolone reverses neurogenic and cognitive deficits in mouse model of Alzheimer's disease","volume":"107","author":"Wang","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/j.neuroscience.2024.11.078_b0935","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/bph.13699","article-title":"Selection and early clinical evaluation of the brain\u2010penetrant 11\u03b2\u2010hydroxysteroid dehydrogenase type 1 (11\u03b2\u2010HSD1) inhibitor UE2343 (Xanamem\u2122)","volume":"174","author":"Webster","year":"2017","journal-title":"Br. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.neuroscience.2024.11.078_b0940","article-title":"VALZ\u2010Pilot: High\u2010dose valacyclovir treatment in patients with early\u2010stage Alzheimer's disease","volume":"8","author":"Weidung","year":"2022","journal-title":"Alzheimers Dement (n y)"},{"issue":"4","key":"10.1016\/j.neuroscience.2024.11.078_b0945","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.tins.2018.01.010","article-title":"Long road to ruin: noradrenergic dysfunction in neurodegenerative disease","volume":"41","author":"Weinshenker","year":"2018","journal-title":"Trends Neurosci."},{"issue":"2","key":"10.1016\/j.neuroscience.2024.11.078_b0950","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/ana.25513","article-title":"Target engagement in an Alzheimer trial: Crenezumab lowers amyloid \u03b2 oligomers in cerebrospinal fluid","volume":"86","author":"Yang","year":"2019","journal-title":"Ann. Neurol."},{"issue":"3","key":"10.1016\/j.neuroscience.2024.11.078_b0955","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/alz.12845","article-title":"Nutritional metabolism and cerebral bioenergetics in Alzheimer's disease and related dementias","volume":"19","author":"Yassine","year":"2023","journal-title":"Alzheimers Dement."},{"issue":"1","key":"10.1016\/j.neuroscience.2024.11.078_b0960","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2174\/187152411794961040","article-title":"p38 MAP kinase inhibitors as potential therapeutic drugs for neural diseases","volume":"11","author":"Yasuda","year":"2011","journal-title":"Cent NervSyst Agents Med Chem"},{"issue":"1","key":"10.1016\/j.neuroscience.2024.11.078_b0965","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13195-020-0580-2","article-title":"Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer\u2019s disease","volume":"12","author":"Yoshida","year":"2020","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"10.1016\/j.neuroscience.2024.11.078_b0970","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40035-023-00336-2","article-title":"Combined metabolic activators improve cognitive functions in Alzheimer\u2019s disease patients: a randomised, double-blinded, placebo-controlled phase-II trial","volume":"12","author":"Yulug","year":"2023","journal-title":"Translational Neurodegeneration"}],"container-title":["Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306452224006973?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306452224006973?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T01:43:54Z","timestamp":1736214234000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306452224006973"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":192,"alternative-id":["S0306452224006973"],"URL":"https:\/\/doi.org\/10.1016\/j.neuroscience.2024.11.078","relation":{},"ISSN":["0306-4522"],"issn-type":[{"value":"0306-4522","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u201cCurrent and emerging drug therapies in Alzheimer\u2019s disease: A pathophysiological Perspective\u201d","name":"articletitle","label":"Article Title"},{"value":"Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuroscience.2024.11.078","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Brain Research Organization (IBRO). Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}